Literature DB >> 10524579

How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?

G W Comstock1.   

Abstract

Recommendations regarding how long isoniazid should be taken to prevent tuberculosis have gradually shifted from 12 to 6 months of treatment. These recommendations and the relevant evidence from controlled trials on duration of treatment are reviewed. The conclusions for immunocompetent adults are: 1) 6 months of preventive treatment does not give optimal protection; 2) more than 12 months of preventive treatment is not necessary; 3) 9-10 months appears to be the optimal duration; and 4) total duration of preventive treatment may be more important than its continuity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10524579

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  84 in total

Review 1.  Latent tuberculosis infection: old problem, new priorities.

Authors:  Kevin Schwartzman
Journal:  CMAJ       Date:  2002-03-19       Impact factor: 8.262

2.  Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents.

Authors:  D E Furst; J Cush; S Kaufmann; J Siegel; R Kurth
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

3.  Screening immigrants to Canada for tuberculosis: chest radiography or tuberculin skin testing?

Authors:  Dick Menzies
Journal:  CMAJ       Date:  2003-11-11       Impact factor: 8.262

Review 4.  Paediatric tuberculosis.

Authors:  W Hoskyns
Journal:  Postgrad Med J       Date:  2003-05       Impact factor: 2.401

5.  Evidence-based clinical guidelines for immigrants and refugees.

Authors:  Kevin Pottie; Christina Greenaway; John Feightner; Vivian Welch; Helena Swinkels; Meb Rashid; Lavanya Narasiah; Laurence J Kirmayer; Erin Ueffing; Noni E MacDonald; Ghayda Hassan; Mary McNally; Kamran Khan; Ralf Buhrmann; Sheila Dunn; Arunmozhi Dominic; Anne E McCarthy; Anita J Gagnon; Cécile Rousseau; Peter Tugwell
Journal:  CMAJ       Date:  2010-06-07       Impact factor: 8.262

6.  Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.

Authors:  Eric Nuermberger; Sandeep Tyagi; Kathy N Williams; Ian Rosenthal; William R Bishai; Jacques H Grosset
Journal:  Am J Respir Crit Care Med       Date:  2005-09-08       Impact factor: 21.405

7.  Trends in influenza vaccination coverage rates in Germany over six seasons from 2001/02 to 2006/07.

Authors:  Patricia R Blank; Andreas U Freiburghaus; Bernhard R Ruf; Matthias M Schwenkglenks; Thomas D Szucs
Journal:  Med Klin (Munich)       Date:  2009-01-23

Review 8.  Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration.

Authors:  Nicole Salazar-Austin; David W Dowdy; Richard E Chaisson; Jonathan E Golub
Journal:  Am J Epidemiol       Date:  2019-12-31       Impact factor: 4.897

Review 9.  Updated diagnosis and treatment of childhood tuberculosis.

Authors:  Shou-Chien Chen; Kwo-Liang Chen; Kou-Huang Chen; Shun-Tien Chien; Kow-Tong Chen
Journal:  World J Pediatr       Date:  2013-02-07       Impact factor: 2.764

10.  Long-term effectiveness of diagnosing and treating latent tuberculosis infection in a cohort of HIV-infected and at-risk injection drug users.

Authors:  Jonathan E Golub; Jacquie Astemborski; Mohammed Ahmed; Wendy Cronin; Shruti H Mehta; Gregory D Kirk; David Vlahov; Richard E Chaisson
Journal:  J Acquir Immune Defic Syndr       Date:  2008-12-15       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.